title: [The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].
abstract: OBJECTIVE
  Epidemiological studies have shown that low levels of dehydroepiandrosterone might increase the risk of developing metabolic syndrome. The aim of this study was to evaluate whether dehydroepiandrosterone supplementation in schizophrenic patients treated with olanzapine would influence the anthropometric and biochemical parameters of metabolic syndrome.
  
  
  METHODS
  Male schizophrenic patients (no=55) participated in a twelve-week, randomized, double blind, placebo controlled study. They received 100 mg dehydroepiandrosterone (DHEA) or placebo as an augmentation of olanzapine treatment (an average dosage 15 mg/day). Main outcomes of the study were changes in lipid profile, fasting glucose levels, body mass index and waist circumference values.
  
  
  RESULTS
  Forty five patients completed the study. There were no major changes in the overall cholesterol value, HDL cholesterol, LDL cholesterol or triglycerides in either group. The results of the repeated measures analysis of the system: fasting glucose level 2x, (at the beginning and end of the study), 2x (the study group and the control group), showed a significant interaction (F =5.7, df= 1.000 p= 0.021). The blood glucose level was decreased in the DHEA group. Furthermore, increases in waist circumference (delta= -1.11, t=-2.87; df=20; p=0.01) and BMI value (delta= -0.48, t=-2.38; df=19; p=0.028) were observed in the placebo group.
  
  
  CONCLUSIONS
  Dehydroepiandrosterone supplementation results in stabilization of BMI, waist circumference and fasting glycaemia values in schizophrenic patients treated with olanzapine. To confirm the insulin-like effect of dehydroepiandrosterone, long-term research concentrating on the evaluation of glucose metabolism has to be performed.
authors.affiliation: III Klinika Psychiatryczna, Instytut Psychiatrii i Neurologii.
authors.forename: Justyna Anna
authors.initials: JA
authors.lastname: Holka-Pokorska
authors.affiliation: Prywatna Praktyka Psychoterapeutów Psychoanalitycznych "Psychoterapeuci na Francuskiej"
authors.forename: Rafał
authors.initials: R
authors.lastname: Radzio
authors.affiliation: III Klinika Psychiatryczna, Instytut Psychiatrii i Neurologii.
authors.forename: Marek
authors.initials: M
authors.lastname: Jarema
authors.affiliation: III Klinika Psychiatryczna, Instytut Psychiatrii i Neurologii.
authors.forename: Adam
authors.initials: A
authors.lastname: Wichniak
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000494:pharmacology; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000494:pharmacology; D001786:Blood Glucose / Q000187:drug effects; D015992:Body Mass Index; D003687:Dehydroepiandrosterone / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D006801:Humans; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects; D052439:Lipid Metabolism Disorders / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D000077152:Olanzapine; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D055815:Young Adult
chemical_list: D000276:Adjuvants, Immunologic; D014150:Antipsychotic Agents; D001786:Blood Glucose; D001569:Benzodiazepines; D003687:Dehydroepiandrosterone; D000077152:Olanzapine
keywords: dehydroepiandrosterone; metabolic syndrome; schizophrenia